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f d. Note - This overview was originally presented at the 
International Symposium on Clinical Disorders of Bone 
and Mineral Metabolism, May 9-13,1983. The following 
list indicates the presentations given in this session at the 
Symposium and the contents ofthe corresponding chap-
ter in the Proceedings of the Symposium published by 
Excerpta Medica. The numbers in parentheses refer to 
pages in this volume. Complete information about the 
contents ofthe Proceedings can be found at the back of 
this issue. 
Idiopathic hypercalciuria. E.L. Coe (403) 
Separate pathogenetic origins for absorptive and renal 
hypercalciurias: Different responses to treatment. C Y . C 
Pak and J.E. Zerwekh (406) 
The role of serum 1,25(OHy-vitamin D concentrations 
determining urinary calcium excretion. J. Lemann Jr, 
R.W. Gray, and W.J. Maierhofer (411). 
Idiopathic normocalcemic hypercalciuria is certainly 
the commonest metabolic disorder observed in patients 
with calcium stones, and there is much evidence that 
hypercalciuria directly causes stones. The evidence relates 
high urine calcium levels to increased urine calcium 
oxalate supersaturation. High supersaturation to genesis 
of calcium stones, which is widely accepted, is reviewed 
in the fol lowing three papers. 
A general consensus, drawn from many sources, indi-
cates that reduction of urine calcium levels leads to a 
concomitant and impressive reduction of new stone 
product ion. At the moment, the principal uncertainties 
concern the mechanism by which urine calcium excre-
t ion is elevated and, in a related sense, the biochemical 
and clinical effects of measures taken to lower urine 
calcium in treatment of stone. Data that bear on the 
subject were presented by Lemann, et al (pp. 411 ff.). He 
and his colleagues have shown clearly that administra-
t ion of slight excesses of 1,25(OH)2D3 to normal people 
causes fasting hypercalciuria and hypercalciuria on a low 
calcium diet. On a very low calcium diet, the urine cal-
cium level may exceed dietary intake. These data suggest 
that a modest disorder of vitamin D metabolism, leading 
to a slight excess in the production of 1,25(OH)2D3, could 
easily give rise not only to hypercalciuria but to an intol-
erance of the low calcium diet. It could also give rise to 
fasting hypercalciuria, which could easily be confused 
with renal hypercalciuria. 
Pak and Zerwekh (pp. 406 ff.) clearly indicated that, clini-
cally, patients divide themselves into those with predom-
inant overabsorption of calcium and those who have 
fasting hypercalciuria and appear to have a defective 
renal tubule calcium reabsorption. Clinical and labora-
tory observations clearly depict the heterogeneity of phy-
siological response in the syndrome, and, interestingly, 
are compatible with the effects of 1,25(OH)2D3 adminis-
tration in normals. In noting response to treatment, Pak 
pointed out that patients with reduced renal calcium 
conservation seem to do well with thiazide and those 
who present principally with intestinal hyperabsorption 
probably can be treated with sodium cellulose phosphate. 
Material f rom our own group is consistent with the Pak 
data and with the Lemann experiments on 1,25D3 ad min-
istration. We described (pp. 403 ff.) a continuous spec-
t rum of behavior in hypercalciuric subjects. At one end 
are patients who conserve very well when challenged 
with a low calcium diet, and at the other end are patients 
who cannot conserve calcium well at all. Uniformly, 
hypercalciuric patients have low levels of serum PTH, 
and under conditions of low calcium diets the patients 
generally manifest a serum calcium level higher than that 
of normal subjects given the same diets. Despite the 
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Fig.1 
Calc ium stone fo rmat ion before and du r ing t reatment of hypercalc i -
uria w i th th iaz ide. Each pat ient is shown as a hor izonta l l ine : new 
stones, closed symbols; mu l t ip le stones occurr ing in clusters, open 
symbols. Repr in ted w i th permission f rom Hypercalc iur ic States, 
Crune & Stratton, 1983. 
higher calcium level in the blood and lower PTH, how-
ever,and equivalent levelsof serum phosphorus,patients 
with hypercalciuria have the same levels of serum 
1,25(OH)2D3. The best explanation for the spectrum of 
behavior observed in hypercalciuria in response to a low 
calcium diet is a subtle but persistent disorder of 
1,25(OH)2D3 regulation. 
From these three papers, and in the context of what is 
known about this disorder, the hypothesis emerges that 
a regulation disorder of 1,25(OH)2D3 may explain the 
complex and variable behavior of patients. Some can 
benefit f rom drugs that reduce calcium absorption and 
some benefit f rom thiazide. A final answer to treatment 
must await a definit ive analysis of vitamin D metabolism, 
which is not yet available. 
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